
CRBP Stock Forecast & Price Target
CRBP Analyst Ratings
Bulls say
Corbus Pharmaceuticals is an innovative biopharmaceutical company with a diverse pipeline of therapies targeting various oncological and metabolic conditions. The company's CRB-701, CRB-601, and CRB-913 show promising results in clinical trials, with strong efficacy and safety profiles. With a clear regulatory path and a strategic enrollment strategy in place, Corbus is well-positioned for success, and the potential launch of its therapies could drive significant financial growth in the future.
Bears say
Corbus Pharmaceuticals is focused on developing innovative therapies in oncology and obesity, with a focus on targeting well-understood biological pathways. However, the company's financial and clinical data suggest a lack of success in bringing these therapies to market, leading to a negative outlook on the stock's potential for growth and profitability. The company's recent data updates show a potential for a high unmet need in the target population, but questions remain regarding the feasibility and effectiveness of their treatment options. Based on this, the analyst maintains an OUTPERFORM rating and adjusts the price target to $30, anticipating a more conservative market for their Nectin-4 targeted therapy, CRB-701.
This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.
CRBP Analyst Forecast & Price Prediction
Start investing in CRBP
Order type
Buy in
Order amount
Est. shares
0 shares